NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 3 September 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Richard Ballerand – TAC A Volunteer Present for all items
4. Dr Alex Cale Present for items 1 to 4.3.2
5. Paul Caulfield – TAC D Volunteer Present for all items
6. Michael Chambers Present for items 1 to 4.3.2, 6 to 6.2.2
7. Dawn Cooper Present for all items
8. Dr Mark Corbett Present for all items
9. Dr Prithwiraj Das Present for all items
10. Dr David Foreman Present for all items
11. Tina Garvey – HST Volunteer Present for items 1 to 4.3.2
12. Dr Pedro Saramago Goncalves Present for all items
13. John Hampson Present for all items
14. Iain McGowan Present for all items
15. Ugochi Nwulu Present for all items
16. Stella O’Brien Present for all items
17. Dr Clare Offer Present for all items
18. Dr Kate Ren Present for items1 to 4.3.2, 6 to 6.2.2
19. Dr Arpit Srivastava Present for all items
20. Alan Thomas – TAC A Volunteer Present for all items
21. Elizabeth Thurgar Present for items 1 to 5.2.2
22. Dr Satish Venkateshan Present for items 1 to 5.2.2
23. Simon Watts Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Items 1 to 5.2.2

Ross Dent, Associate Director Items 6 to 6.2.2

Celia Mayers, Project Manager Items 1 to 5.2.2

Louise Jafferally, Project Manager Items 6 to 6.2.2

Alex Filby, Heath Technology Assessment Adviser Items 1 to 4.3.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5 to 5.2.2

Giacomo De Guisa, Heath Technology Assessment Analyst Items 1 to 4.3.2

Owen Swales, Heath Technology Assessment Analyst Items 5 to 5.2.2

George Millington, Heath Technology Assessment Analyst Items 6 to 6.2.2

External assessment group representatives present

Lena Alkudiary, Warwick Evidence Items 1 to 4.2.1

Henry Nwanko, Warwick Evidence Items 1 to 4.2.1

Stephen Rice, Newcastle Technology Assessment Review Group Items 5 to 5.1.3

Giovany Orozco Leal, Newcastle Technology Assessment Review Group Items 5 to 5.1.3

Rebecca Bresnahan, Liverpool Reviews and Implementation Group (LRiG), items 6 to 6.13

James Mahon, Liverpool Reviews and Implementation Group (LRiG), items 6 to 6.13

Clinical, Patient & NHS England experts present

Manoel Filho, Community expert, nominated by UK-CAB, items 1 to 4.1.3

Rachael Jones, Consultant at Chelsea and Westminster Hospital NHS Foundation Trust, clinical expert nominated by NHS England, items 1 to 4.1.3

Michael Brady, Consultant in HIV and Sexual Health at King’s College Hospital – clinical expert nominated by ViiV (company), items 1 to 4.1.3

Sophie Brady, Clinical Director and Consultant in Genitourinary Medicine at Locala CIC (and Bradford Teaching Hospitals NHS F T), clinical expert nominated by BASHH, items 1 to 4.1.3

Anna Kafkalia, Advanced PH Lead, Sexual Health Commissioning Lead at Liverpool City Council, commissioning expert nominated by English HIV and Sexual Health Commissioners Group (EHSHCG), items 1 to 4.1.3

James Woolgar, Advanced PH Lead, Sexual Health Commissioning Lead at Liverpool City Council, commissioning expert, nominated by English HIV and Sexual Health Commissioners Group (EHSHCG), items 1 to 4.1.3

Sanjeev Patel, Clinical Lead for Innovative Medicine Fund (IMF), NHS England, items 1 to 4.3

Professor David Jones, Professor of Liver Immunology, Clinical expert, nominated by Ipsen, items 5 to 5.1.3

Professor Palak Trivedi, Consultant Hepatologist and Associate Professor of Cholestatic Liver Disease, Clinical expert nominated by the British Association for the Study of the Liver, items 5 to 5.1.3

Mo Christie, Head of Patient Services at PBC Foundation, Patient expert nominated by the PBC Foundation, items 5 to 5.1.3

Lisa Woodcock, Patient expert nominated by British Liver Trust, items 5 to 5.1.3

Lydia Ball, National Programme of Care Senior Manager**,** NHS Commissioning expert, nominated by NHSE, items 5 to 5.1.3

Professor Peter Clark, CDF Lead, NHS England, items 6 to 6.2.2

Dr Rakesh Popat, Consultant Haematologist, clinical expert nominated by Johnson & Johnson Innovative Medicine, items 6 to 6.13

Dr Karthik Ramasamy, Associate Professor and Consultant Haematologist, clinical expert nominated by the UK Myeloma Society, items 6 to 6.13

Caroline Donoghue, Senior Policy Officer, Myeloma UK, patient expert nominated by Myeloma UK, items 6 to 6.13

Kathryn Oddie, Patient expert, nominated by Myeloma UK, items 6 to 6.13

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair – Professor Stephen O’Brien - welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Amit Parekh, Professor Andrew Renehan, Louise Hunt, Dr Steve Lloyd.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 6 August 2024.

### Appraisal of cabotegravir for preventing HIV-1 in adults and young people [ID6255]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from ViiV Healthcare (GSK).
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11304/documents)
		3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Alex Cale, Dr Mark Corbett, Stella O’Brien.
	2. Part 2a – Closed session (members of the public, clinical, community and commissioning experts and company representatives were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11304>

### Appraisal of elafibranor for treating primary biliary cholangitis [ID6331]

* 1. Part 1 – Closed session - the Medicines and Healthcare products Regulatory Agency (MHRA) has not yet given its regulatory opinion for this appraisal, and therefore this discussion will take place in a part 2 session, which is closed to public observers.
		1. The chair welcomed the invited experts, external assessment group representatives, and company representatives from Ipsen.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11378/documents).
		3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Pedro Saramago Goncalves, Dr Arpit Srivastava and Ugochi Nwulu.
	2. Part 2 – Closed session (company representatives, clinical, patient and commissioning experts and external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11378/documents>

### Appraisal of teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Johnson & Johnson Innovative Medicine.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11418/documents)
		3. The chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11418>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 2 October 2024 and will start promptly at 9am.